ADC Therapeutics is seeking review from the FDA regarding the sBLA submission for its product, ZYNLONTA.

The entities involved

• ADC Therapeutics →

  company in Épalinges, Switzerland

  Nothing else this week.

• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31

Related events

• The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.Jun 7
• Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
• FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.Oct 13